Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - eformoterol fumarate dihydrate -

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - eformoterol fumarate dihydrate; budesonide -

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; iron oxide yellow; macrogol 400; hypromellose; mannitol; calcium hydrogen phosphate dihydrate; titanium dioxide; magnesium stearate; sodium starch glycollate type a - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, dispersible - excipient ingredients: mannitol; microcrystalline cellulose; crospovidone; xylitol; calcium hydrogen phosphate; sodium stearylfumarate; hyprolose; colloidal anhydrous silica - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - esopreze is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esopreze iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - esopreze is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esopreze iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - benralizumab, quantity: 30 mg - injection, solution - excipient ingredients: polysorbate 20; trehalose; histidine; histidine hydrochloride monohydrate; water for injections - fasenra is indicated as add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count greater than or equal to 300 cells/microlitre or greater than or equal to 150 cells/microlitre if on oral corticosteroid treatment) (see section 5.1 pharmacodynamic properties [clinical trials]).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - benralizumab, quantity: 30 mg - injection, solution - excipient ingredients: polysorbate 20; trehalose; histidine; histidine hydrochloride monohydrate; water for injections - fasenra pen is indicated as add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count greater than or equal to 300 cells/microlitre or greater than or equal to150 cells/microlitre if on oral corticosteroid treatment) (see section 5.1 pharmacodynamic properties [clinical trials]).